Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

BACKGROUND Combination therapy is logical for patients with non-insulin-dependent (type 2) diabetes mellitus, because they often have poor responses to single-drug therapy. We studied the efficacy and physiologic effects of metformin and troglitazone alone and in combination in patients with type 2 diabetes. METHODS We randomly assigned 29 patients to receive either metformin or troglitazone for three months, after which they were given both drugs for another three months. Plasma glucose concentrations during fasting and postprandially and glycosylated hemoglobin values were measured periodically during both treatments. Endogenous glucose production and peripheral glucose disposal were measured at base line and after three and six months. RESULTS During metformin therapy, fasting and postprandial plasma glucose concentrations decreased by 20 percent (58 mg per deciliter [3.2 mmol per liter], P<0.001) and 25 percent (87 mg per deciliter [4.8 mmol per liter], P<0.001), respectively. The corresponding decreases during troglitazone therapy were 20 percent (54 mg per deciliter [2.9 mmol per liter], P=0.01) and 25 percent (83 mg per deciliter [4.6 mmol per liter], P<0.001). Endogenous glucose production decreased during metformin therapy by a mean of 19 percent (P=0.001), whereas it was unchanged by troglitazone therapy (P=0.04 for the comparison between groups). The mean rate of glucose disposal increased by 54 percent during troglitazone therapy (P=0.006) and 13 percent during metformin therapy (P= 0.03 for the comparison within the group and between groups). In combination, metformin and troglitazone further lowered fasting and postprandial plasma glucose concentrations by 18 percent (41 mg per deciliter [2.3 mmol per liter], P=0.001) and 21 percent (54 mg per deciliter [3.0 mmol per liter], P<0.001), respectively, and the mean glycosylated hemoglobin value decreased 1.2 percentage points. CONCLUSIONS Metformin and troglitazone have equal and additive beneficial effects on glycemic control in patients with type 2 diabetes. Metformin acts primarily by decreasing endogenous glucose production, and troglitazone by increasing the rate of peripheral glucose disposal.

[1]  R. DeFronzo.  The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM , 1988, Diabetes.

[2]  K. Kosaka,et al.  Effects of Troglitazone: A new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy , 1996, Diabetes Care.

[3]  K. Kosaka,et al.  Effect of Combination Therapy of Troglitazone and Sulphonylureas in Patients with Type 2 Diabetes Who Were Poorly Controlled by Sulphonylurea Therapy Alone , 1996, Diabetic medicine : a journal of the British Diabetic Association.

[4]  M. Toeller.  α‐Glucosidase inhibitors in diabetes: efficacy in NIDDM subjects , 1994, European journal of clinical investigation.

[5]  H. Vestergaard,et al.  Sulfonylurea therapy improves glucose disposal without changing skeletal muscle GLUT4 levels in noninsulin-dependent diabetes mellitus subjects: a longitudinal study. , 1995, The Journal of clinical endocrinology and metabolism.

[6]  K. Heidenreich,et al.  In vitro studies on the action of CS-045, a new antidiabetic agent. , 1990, Metabolism: clinical and experimental.

[7]  J. Olefsky,et al.  Metabolic Effects of Troglitazone on Fructose-Induced Insulin Resistance in the Rat , 1994, Diabetes.

[8]  L. S. Hermann,et al.  Therapeutic Comparison of Metformin and Sulfonylurea, Alone and in Various Combinations: A double-blind controlled study , 1994, Diabetes Care.

[9]  F. Féry,et al.  Effects of metformin on the pathways of glucose utilization after oral glucose in non-insulin-dependent diabetes mellitus patients. , 1997, Metabolism: clinical and experimental.

[10]  F. Ashcroft.  Mechanisms of the Glycaemic Effects of Sulfonylureas , 1996, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[11]  A. Saltiel,et al.  Metabolic effects of troglitazone in the Goto-Kakizaki rat, a non-obese and normolipidemic rodent model of non-insulin-dependent diabetes mellitus. , 1997, Metabolism: clinical and experimental.

[12]  R. DeFronzo,et al.  Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. , 1995, The New England journal of medicine.

[13]  P. Fernyhough,et al.  Role of Neurotrophins in Diabetic Neuropathy and Treatment with Nerve Growth Factors , 1997, Diabetes.

[14]  G. Reaven,et al.  Effect of time on measurement of hepatic glucose production. , 1988, The Journal of clinical endocrinology and metabolism.

[15]  W. Sheu,et al.  Effect of Glipizide Treatment on Response to an Infused Glucose Load in Patients With NIDDM , 1995, Diabetes Care.

[16]  J. Olefsky,et al.  Thiazolidinediones in the Treatment of Insulin Resistance and Type II Diabetes , 1996, Diabetes.

[17]  R. DeFronzo,et al.  Glucose clamp technique: a method for quantifying insulin secretion and resistance. , 1979, The American journal of physiology.

[18]  T. Dornan,et al.  Double-Blind Evaluation of Efficacy and Tolerability of Metformin in NIDDM , 1991, Diabetes Care.

[19]  J. Olefsky,et al.  Metabolic Effects of New Oral Hypoglycemic Agent CS-045 in NIDDM Subjects , 1992, Diabetes Care.

[20]  G Dailey,et al.  Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. , 1995, The New England journal of medicine.

[21]  R. Shulman,et al.  Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study. , 1992, The Journal of clinical investigation.

[22]  R. DeFronzo,et al.  Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. , 1987, The Journal of clinical investigation.

[23]  T. Koschinsky,et al.  Oral antidiabetic combination therapy with sulphonylureas and metformin. , 1991, Diabete & metabolisme.